DUBLIN--(BUSINESS WIRE)--Jul 30, 2018--The "2018 Essential Hypertension Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Essential Hypertension Market" report has been added to ResearchAndMarkets.com's offering. 2018 Essential Hypertension Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Essential Hypertension Market is a comprehensive report on Essential Hypertension market. To assist researchers, investors and business development managers, the publisher has come up with a comprehensive report on Essential Hypertension pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials. Drugs under development directly and through combination with other drugs are also included. Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Essential Hypertension pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report. In addition to complete details of each product, the report provides key trends in Essential Hypertension pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development. Companies Mentioned

Actelion Ltd Bayer AG Beijing CoSci Med-Tech Co.,Ltd Boryung Pharmaceutical Co., Ltd Chong Kun Dang Pharmaceutical Corp. Daiichi Sankyo Company, Limited HanAll Biopharma Co., Ltd. Hypogen, Inc. Il Dong Pharmaceutical Co Ltd Merck KGaA Novartis International AG Quantum Genomics SA RMJ Holdings, LLC Shin Poong Pharmaceutical Co Ltd Takeda Pharmaceutical Company Limited Theracos, Inc. Yuhan Co, Ltd.

Key Topics Covered: 1 Table of Contents 2 Essential Hypertension Pipeline Analysis 3 Essential Hypertension- Company Wise Pipeline Analysis 4 Essential Hypertension R&D Pipeline Snapshots 5 Recent Developments in Essential Hypertension Pipeline 6 Appendix For more information about this report visit https://www.researchandmarkets.com/research/bnksp4/essential?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005343/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Cardiovascular Drugs ,Clinical Trials



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/30/2018 07:28 AM/DISC: 07/30/2018 07:28 AM